Optimizing the use of biological therapy in patients with inflammatory bowel disease

por Moss, Alan C.
Publicado 2015

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

por Lawlor, Garrett, Moss, Alan C
Publicado 2009

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine

por Nanda, Kavinderjit, Moss, Alan C
Publicado 2012

Exosomes in Intestinal Inflammation

por Ayyar, Kanchana K., Moss, Alan C.
Publicado 2021

Implications of recurrent SARS-CoV-2 outbreaks for IBD management

por Segal, Jonathan P, Moss, Alan C
Publicado 2020

Nephrolithiasis in patients with inflammatory bowel disease in the community

por Cury, Dídia Bismara, Moss, Alan C, Schor, Nestor
Publicado 2013

Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis

por Gonzalez-Suarez, Begoña, Sengupta, Shreyashee, Moss, Alan C
Publicado 2017

Management of Asymptomatic Terminal Ileitis

por Donet, Jean A, Charabaty, Aline, Moss, Alan C
Publicado 2020

In Silico Promoter Analysis can Predict Genes of Functional Relevance in Cell Proliferation: Validation in a Colon Cancer Model

por Moss, Alan C., Doran, Peter P., MacMathuna, Padraic
Publicado 2007

In silico gene expression analysis – an overview

por Murray, David, Doran, Peter, MacMathuna, Padraic, Moss, Alan C
Publicado 2007

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis

por Devlen, Jennifer, Beusterien, Kathleen, Yen, Linnette, Ahmed, Awais, Cheifetz, Adam S., Moss, Alan C.
Publicado 2014

Endogenous antisense RNA curbs CD39 expression in Crohn’s disease

por Harshe, Rasika P., Xie, Anyan, Vuerich, Marta, Frank, Luiza Abrahão, Gromova, Barbora, Zhang, Haohai, Robles, Rene’ J., Mukherjee, Samiran, Csizmadia, Eva, Kokkotou, Efi, Cheifetz, Adam S., Moss, Alan C., Kota, Satya K., Robson, Simon C., Longhi, Maria Serena
Publicado 2020

Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists

por Chen, Jiaxuan, Haller, Carolyn A., Jernigan, Finith E., Koerner, Steffi K., Wong, Daniel J., Wang, Yiqiang, Cheong, Jae Eun, Kosaraju, Revanth, Kwan, Julian, Park, Diane D., Thomas, Beena, Bhasin, Swati, De La Rosa, Roberto C., Premji, Alykhan M., Liu, Liying, Park, Eden, Moss, Alan C., Emili, Andrew, Bhasin, Manoj, Sun, Lijun, Chaikof, Elliot L.
Publicado 2020